Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors. [PDF]
ACS Med Chem Lett, 2014 Radwan MF, Dalby KN, Kaoud TS.
europepmc +1 more source
Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. [PDF]
Ther Adv Drug Saf, 2017 Fanelli A, Ghisi D, Aprile PL, Lapi F.
europepmc +1 more source
Comparison of benefit-risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments. [PDF]
Patient Prefer Adherence, 2016 Byun JH +5 more
europepmc +1 more source
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease. [PDF]
Cochrane Database Syst Rev, 2014 Miao XP +5 more
europepmc +1 more source
Clinical Profile of Cyclooxygenase-2 Inhibitors in Treating Non-Small Cell Lung Cancer: A Meta-Analysis of Nine Randomized Clinical Trials. [PDF]
PLoS One, 2016 Zhou YY, Hu ZG, Zeng FJ, Han J.
europepmc +1 more source
Opioid-sparing effect of selective cyclooxygenase-2 inhibitors on surgical outcomes after open colorectal surgery within an enhanced recovery after surgery protocol. [PDF]
World J Gastrointest Oncol, 2016 Lohsiriwat V.
europepmc +1 more source
Association of COX-2 Selectivity in Pain Medication Use with Endometriosis Incidence: Retrospective Cohort Study. [PDF]
Yonsei Med JPark J +6 more
europepmc +1 more source
Exploring the potential of <i>Laportea decumana</i> extract compounds as COX-1 and COX-2 inhibitors: An in silico study. [PDF]
Narra JSimaremare ES +3 more
europepmc +1 more source
Incidence rates of tuberculosis and inflammatory bowel disease in patients with ankylosing spondylitis treated with biologics in Korea. [PDF]
Rheumatology (Oxford)Kwon OC +6 more
europepmc +1 more source